Oncology Clinical Development Expertise

Cancer Clinical Development is Complex, Our Experts Can Help

Veristat has extensive experience supporting >560 oncology projects and >70 oncology marketing applications in the United States, Europe, and Japan. We help oncology developers navigate the complexities of designing and executing their cancer trials in the most highly competitive and complicated market. Our extensive expertise includes traditional cancer treatments, devices/diagnostics as well as specialized therapies including vaccines, gene therapies, cell therapies, and immunotherapies. 

Oncology Experience

With cancer being the second* leading cause of death today, it’s no wonder that Veristat’s clients are prioritizing their pipelines to develop life-extending cancer therapies. 

Veristat's teams work on a spectrum of amazing cancer treatments including drugs, vaccines, and diagnostics.

  • Cancer clinical development comprises >35% of the work we do
  • Cancer treatments account for 50% of the marketing applications that our teams have prepared, 
  • In the past 5 years, 10 oncology products were approved for NDAs and jNDAs that we prepared

*Source: http://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm


Experience in Blood Cancers & Solid Tumors

Hematologic Malignancies/Blood Cancers
   Acute Myeloid Leukemia (AML)     Metastatic Non-Hematologic Malignancies 
   B-Cell Lymphoma     Multiple Myeloma (MM) 
   Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)     Myelodysplastic Syndromes (MDS) 
   Chronic Lymphocytic Leukemia (CLL)     Myeloid Leukemia 
   Cutaneous T-Cell Lymphoma (CTCL)     Myeloproliferative Neoplasm 
   Diffuse Large B-Cell Lymphoma (DLBCL)     Non-Hodgkin's Lymphoma (NHL) 
   Essential Thrombocythemia     Peripheral T-cell Lymphoma (PTCL) 
   Follicular Lymphoma     Richter's Transformation (RT) 
   Hodgkin’s Lymphoma     Systemic Mastocytosis (SM) 
   Mantle Cell Lymphoma     T Cell Lymphoma 
   Mantle Cell NHL     Waldenstrom's Macroglobulinemia 


Solid Tumor Indications
   Advanced/Metastatic Solid Tumors    Melanoma
   Biliary Cancer    Non-Small Cell Lung Cancer (NSCLC)
   Bladder Cancer    Ovarian Cancer
   Brain Cancer    Pancreatic Cancer
   Breast Cancer    Prostate Cancer
   Cervical Cancer / Dysplasia    Rectal Cancer
   Cholangiocarcinoma/Bile Duct    Renal Cell Carcinoma (RCC)
   Colorectal Cancer    Small Cell Lung Cancer (SCLC)
   Gastric Cancer    Synovial Tumors
   Head & Neck Tumors    Thyroid Cancer
   Hepatocellular Carcinoma (HCC)    Urothelial Carcinoma
   Human Papilloma Virus (HPV) Cancers    Vulva Cancer


Customized Oncology Solutions

Cancer Diagnostic Imaging
   Lymph Node Imaging- MRI Contract Agent    Mammography for Breast Cancer Diagnosis 
   Lymph Node Imaging for Prostate Cancer    


Chemotherapy Side Effects
   Chemotherapy-induced Alopecia     Chemotherapy Induced Pain Management 
   Chemotherapy-induced nausea and vomiting (CINV)     Chemotherapy Induced Peripheral Neuropathy 


Our solutions span the entire clinical development life-cycle - and are offered as a comprehensive, all-inclusive solution or as functional support. We offer strategic guidance for informed decision-making, operational support to mitigate trial risks, the statistical knowledge to prove safety and efficacy, the medical oversight to ensure patient safety, and the regulatory expertise to achieve approval success.


Solutions Span Early to Late Phase


Learn More with These Resources


Marketing Applications Approval Record

Veristat is proud to have supported the preparation of 75 marketing applications (NDA, BLA, MAA, etc) that are now approved for patients. For these approved products, ...


Webinar Presentation

Webinar Presentation: Expanding your Clinical Trial into ...

Get the webinar presentation  on how, why and when to expand your clinical trial program into the US, including differences between IND and CTA.


Webinar Video Replay

A Webinar Replay | Expanding your Clinical Trial into the ...

Watch the on-demand webinar  on how, why and when to expand your clinical trial program into the US, including differences between IND and CTA

Request A Proposal